Future Of ESAs In Oncology Uncertain After Takeda Stops Development Of Hematide For CIA
This article was originally published in PharmAsia News
You may also be interested in...
Fresh Concerns Over Biosimilar ESA Use In Thailand Raises Takeda’s Hematide Prospects
SHANGHAI - Fresh safety concerns could be raised over the use of biosimilar erythropoietin stimulating agents after a patient in Thailand, who received an epoetin alfa biosimilar, developed ESA-related pure red cell aplasia, according to Baird analyst Christopher Raymond
Fresh Concerns Over Biosimilar ESA Use In Thailand Raises Takeda’s Hematide Prospects
SHANGHAI - Fresh safety concerns could be raised over the use of biosimilar erythropoietin stimulating agents after a patient in Thailand, who received an epoetin alfa biosimilar, developed ESA-related pure red cell aplasia, according to Baird analyst Christopher Raymond
Takeda, Cell Genesys Halt Phase III Trial Of Cancer Vaccine
U.S.-based Cell Genesys and Japanese partner Takeda Pharmaceutical have stopped a Phase III trial of GVAX, a vaccine they co-developed to prevent prostate cancer. Cell Genesys acted after deaths of trial participants given GVAX exceeded by 20 the number of those on a placebo. The company said it had not identified the cause of the deaths. A spokesman said the firm was reviewing the matter with Takeda and considering a possible change in the business operations between the two partners. (Click here for more